en · de · es · fr · pt
peptide-index.peptides7501.com › Topic › Mechanism And Preclinical Findings — Reference Sheet

Mechanism And Preclinical Findings — Reference Sheet

By Editorial Desk · published 2025-11-21 · last reviewed 2025-12-14 · Topic

REV-ERB raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-12-14 and is reviewed periodically as new material appears.

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Analytical and Handling Considerations

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Related pages on this site

Analytical Detection and Regulatory Status

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Handling, Analysis, and Regulation

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Background from the literature

Naturally occurring lanthanum (57La) is composed of one stable (139La) and one radioactive (138La) isotope, with the stable isotope, 139La, being the most abundant (99.911% natural abundance). There are 39 radioisotopes that have been characterized, with the most stable being 138La, with a half-life of 1.03×1011 years; 137La, with a half-life of 60,000 years and 140La, with a half-life of 40.289 hours. The remaining radioactive isotopes have half-lives that are less than a day and the majority of these less than a minute. This element also has 12 nuclear isomers, the longest-lived of which is 132mLa, with a half-life of 24.3 minutes. Lighter isotopes mostly decay to isotopes of barium and heavy ones mostly decay to isotopes of cerium. 138La can decay to both. The known isotopes of lanthanum range from 116La to 158La.

to improve glycemic control when metformin and/or sulphonylurea (SU) and empagliflozin or linagliptin do not provide adequate glycemic control; when already being treated with the free combination of empagliflozin and linagliptin.

Beef hash Beef and rice Beef stew Chicken and rice Chicken stew Chili con carne Pork and scalloped potatoes Spaghetti with meat sauce Included in the box was a brown-foil accessory packet. The accessory packet contained:

Sources: en.wikipedia.org

Further detail

other metal Any of the metallic elements in the p-block, which are characterized by having a combination of relatively low melting points (all less than 950 K) and relatively high electronegativity values (all more than 1.6, revised Pauling).

The coffee tree produces fruit often referred to as a coffee cherry, but unlike the cherry, which contains a single pit, it most commonly contains two seeds with their flat sides together. The seeds are referred to as beans because of their appearance, though they are not true beans. A few coffee cherries, referred to as "peaberries" contain a single seed; they make up around 10% to 15% of all coffee beans. It is sometimes asserted that because the single bean does not need to share nutrients between two separated beans, it has a superior flavour profile with bright acidity, sweetness, and concentrated and complex flavours, but there is little evidence to support this; for example, peaberries may have been selected from high-quality beans. Coffee trees range from 5 to 10 m (16 to 33 ft) in height. As the tree gets older, it produces less fruit and slowly loses its resistance to pests and diseases. The coffee beans are in the seeds of fruits from trees and shrubs that originally grew naturally in African forests. Humans produce coffee by roasting, grinding and brewing the raw (green) coffee beans. Coffee plants are often grown in rows spaced apart depending on the desired density chosen by the farmer. Some farmers plant shade trees or cash-crop trees, such as orange trees, around them, or plant the coffee on the sides of hills to provide the conditions coffee needs to flourish.

The main issues in the application of this technology are the lack of research into the flow control techniques, accuracy, and precision, the need for simpler operator procedures in the field, and the scaling of production to meet the volume requirements of a global market. This is largely due to the focus in the industry on utilizing the current silicon based manufacturing channels to commercialized LOC technologies more efficiently and economically.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

How is SR9009 detected in laboratory samples?

Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.

Network